Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

Description

The purpose of this study is to find a safe and tolerable way to improve engraftment after transplant. Research studies have shown that adding nicotinamide riboside to donor cells has the potential to increase blood stem cell numbers and potentially decrease the time to engraftment. Also, nicotinamide riboside, TRU NIAGEN (the study drug) is a type of vitamin B supplement that the general public can get without a prescription and is well tolerated.

Conditions

Allogeneic Hematopoietic Cell Transplantation

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to find a safe and tolerable way to improve engraftment after transplant. Research studies have shown that adding nicotinamide riboside to donor cells has the potential to increase blood stem cell numbers and potentially decrease the time to engraftment. Also, nicotinamide riboside, TRU NIAGEN (the study drug) is a type of vitamin B supplement that the general public can get without a prescription and is well tolerated.

A Pilot Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

Condition
Allogeneic Hematopoietic Cell Transplantation
Intervention / Treatment

-

Contacts and Locations

Cleveland

Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States, 44195

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * All disease indications for allogeneic hematopoietic cell transplantation except for myelofibrosis.
  • * Subject must meet program eligibility criteria\* for myeloablative conditioning alloHCT and plan to undergo myeloablative conditioning.
  • * HLA-identical related donor or unrelated human donor source with bone marrow graft.
  • * Subjects must provide a written informed consent.
  • * History of allergy or intolerance to NR precursor compounds, including niacin or nicotinamide
  • * Pregnant or breastfeeding women are excluded from this study since allogeneic HCT is a strict contraindication.
  • * Subjects with uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Case Comprehensive Cancer Center,

Ronald Sobecks, MD, PRINCIPAL_INVESTIGATOR, Cleveland Clinic, Case Comprehensive Cancer Center

Study Record Dates

2026-04-01